Syros Pharmaceuticals Stock News

Syros Pharmaceuticals Inc. (SYRS) shares closed this week 26.0% lower than it did at the end of last week. The stock is currently down 25.8% year-to-date, down 82.8% over the past 12 months, and down 79.3% over the past five years. This week, the Dow Jones Industrial Average fell 2.4%, and the S&P 500 fell 2.8%. Trading Activity Shares traded as high as $3.38 and as low as $2.40 this week.Trading volume this week was 4.7% lower than the 10-day average and 13.0% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.7. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price lags the S&P 500 Index this week, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average this week, lags it on a 1-year basis, and lags it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 328.5% The company's stock price performance over the past 12 months lags the peer average by 156.8% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Syros Pharmaceuticals Inc. (SYRS) shares closed today at 1.9% above its 52 week low of $3.21, giving the company a market cap of $202M. The stock is currently up 0.3% year-to-date, down 72.9% over the past 12 months, and down 72.5% over the past five years. This week, the Dow Jones Industrial Average fell 1.3%, and the S&P 500 fell 2.6%. Trading Activity Trading volume this week was 18.8% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.4. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -117.0% The company's stock price performance over the past 12 months lags the peer average by 140.8% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Syros Pharmaceuticals Inc. (SYRS) shares closed today at 1.5% above its 52 week low of $3.30, giving the company a market cap of $214M. The stock is currently down 68.0% year-to-date, down 71.5% over the past 12 months, and down 72.2% over the past five years. This week, the Dow Jones Industrial Average rose 2.6%, and the S&P 500 rose 3.0%. Trading Activity Trading volume this week was 10.0% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.5. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 125.3% The company's stock price performance over the past 12 months lags the peer average by 129.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Equities analysts predict that Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) will announce earnings per share (EPS) of ($0.44) for the current fiscal quarter, Zacks Investment Research reports. Five analysts have provided estimates for Syros Pharmaceuticals earnings, with estimates ranging from ($0.48) to ($0.38). Syros Pharmaceuticals reported earnings of ($0.61) per share in the same quarter last year, []

Analysts forecast that Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) will post earnings of ($0.44) per share for the current fiscal quarter, according to Zacks. Five analysts have made estimates for Syros Pharmaceuticals earnings, with the highest EPS estimate coming in at ($0.38) and the lowest estimate coming in at ($0.48). Syros Pharmaceuticals posted earnings per share of []

Syros Pharmaceuticals Inc. (NASDAQ:SYRS) concluded the trading at $3.55 on Friday, December 03 with a fall of -7.07% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $3.82 and 5Y monthly beta was reading 1.88. Considering stocks 52-week price range provides that Syros Pharmaceuticals Inc. (SYRS): Significant Improvements, Worth Being Considered Read More »

Nuveen Asset Management LLC increased its holdings in shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) by 23.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 180,514 shares of the companys stock after purchasing an additional 33,901 shares during the []

Brokerages expect Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) to post $5.65 million in sales for the current quarter, according to Zacks. Five analysts have provided estimates for Syros Pharmaceuticals earnings. The highest sales estimate is $6.00 million and the lowest is $5.00 million. Syros Pharmaceuticals posted sales of $5.70 million in the same quarter last year, which []

Northern Trust Corp raised its stake in Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) by 6.6% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 554,422 shares of the companys stock after purchasing an additional 34,517 shares during the quarter. Northern Trust Corp owned []

Tamibarotene Phase 2 AML data is expected in 2022. Positive trial AML or MDS data would lead to an application to the FDA in 2024.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in fireside chats at two upcoming virtual investor conferences. Management will also be available for one-on-one meetings. Piper Sandler 33rd Annual Healthcare Conference Date: Tuesday, November 23, 2021 Presentation Time: A pre-recorded fireside chat will be

Syros Pharmaceuticals, Inc. (SYRS) CEO Nancy Simonian on Q3 2021 Results - Earnings Call Transcript

Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of 4.65% and 11.79%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for th

Syros Pharmaceuticals (NASDAQ:SYRS) is set to give its latest quarterly earnings report on Friday, 2021-11-05. Here's what investors need to know before the announcement.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conferen